Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
+$0.14 today
- Market cap
- $56.57M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
Volume 0.63M
Average 0.42M
CRBP Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $1.87M (cash outflow) rose 173.1% year over year, ahead of the -272.3% change in trailing-twelve-month accounts payables. Sequentially, it rose 231.2% from the prior quarter. Over 3 fiscal years it compounded at +109.1% a year.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +173.1% holds above the trailing-twelve-month pace of -272.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (2.35M) USD
- Year-over-year change
- -246.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.35M) | -246.5% |
| FY2024 | 2024-12-31 | 1.6M | +55.9% |
| FY2023 | 2023-12-31 | 1.03M | +500.4% |
| FY2022 | 2022-12-31 | (256.84K) | +95.7% |
| FY2021 | 2021-12-31 | (5.96M) | — |
Accounts Payables vs competitors
How CRBP compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -272.3% is the lowest of 9, against a peer median of -46.2%.
- Over three fiscal years its annual growth of +109.1% compares with a peer median of +7.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.06M USD | +141.5% | +199.2% | — | |
| LTM Mar 2026 | $7.58M USD | +55.9% | — | 425.1% | |
| LTM Mar 2026 | $5.21M USD | +1496.2% | +17.8% | 992.0% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.83M USD | -230.5% | — | — |
| LTM Mar 2026 | $3.53M USD | -272.3% | +109.1% | — | |
| LTM Mar 2026 | $2.06M USD | -230.7% | -12.7% | — | |
| LTM Mar 2026 | $903K USD | -59.8% | -2.9% | 4.9% | |
| LTM Mar 2026 | $662K USD | -192.7% | — | 20.9% | |
| LTM Mar 2026 | CHF 504.13K CHF | -32.5% | — | — | |
| FY2025 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding CRBP) | — | -46.2% | +7.4% | 20.9% | |
Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (45.64M) | (42.35M) | (44.6M) | (40.21M) | (78.54M) |
| Depreciation & Amortization | 1.64M | 1.49M | 641K | (2.74M) | (1.13M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.48M | 5.72M | 3.47M | 6.15M | 6.29M |
| Change in Working Capital | (15.7M) | (4.02M) | 4.09M | (5.58M) | 9.12M |
| Accounts Receivables | 1.62M | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (5.96M) | (256.84K) | 1.03M | 1.6M | (2.35M) |
| Other Working Capital | (11.36M) | (3.77M) | 3.07M | (7.18M) | 11.47M |
| Other Non-Cash Items | 2.03M | 1.62M | 3.77M | 585K | (229K) |
| Operating Cash Flow | (48.18M) | (37.54M) | (36.1M) | (41.79M) | (64.49M) |
| Capital Expenditures | (54.17K) | (13.45K) | 3 | 0 | (7K) |
| Acquisitions (Net) | 0 | 8.1K | 0 | 0 | 0 |
| Purchases of Investments | (87.27M) | (86.34M) | (33.88M) | (180.8M) | (163.09M) |
| Sales of Investments | 13.88M | 116.42M | 69.53M | 59.49M | 161.46M |
| Other Investing Activities | 23.9K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (73.42M) | 30.07M | 35.64M | (121.31M) | (1.64M) |
| Debt Repayment | 57.78K | (533.62K) | (2.87M) | (15.48M) | 0 |
| Common Stock Issued | 62.59M | 0 | 53.4K | 182.06M | 77.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.82M) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 60.82M | (533.62K) | (2.82M) | 166.58M | 77.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (60.78M) | (8M) | (3.28M) | 3.47M | 11.29M |
| Free Cash Flow | (48.24M) | (37.56M) | (36.1M) | (41.79M) | (64.5M) |
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
Intrinsic Alpha fair value
Locked
Current Price
$2.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.